SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biotechnology company based in Sioux Falls, South Dakota, has received a "Moderate Buy" consensus recommendation from eight equity research firms currently covering the stock, according to MarketBeat. Among these analysts, two have issued sell ratings, five have assigned buy ratings, and one has given a strong buy rating. The average 1-year price target stands at $10.50.
Recent analyst activity reflects a mixed but generally bullish outlook. HC Wainwright lowered its price target from $9.00 to $7.00 while maintaining a buy rating on March 10th. In contrast, Chardan Capital raised its target price from $12.00 to $14.00 and reaffirmed a buy rating on March 11th. Wall Street Zen moved in the opposite direction, downgrading the stock from hold to sell on March 14th. Rodman & Renshaw initiated coverage with a buy rating and a $13.00 price target on April 2nd, while UBS Group assumed coverage in January with a buy rating and a $7.00 target.
The company's recent financial performance has disappointed investors. SAB Biotherapeutics reported earnings per share of ($0.46) for the quarter ending March 9th, missing analyst consensus estimates of ($0.16) by $0.30. Analysts currently project the company will post earnings per share of ($0.72) for the full year.
SAB Biotherapeutics operates as a fully human polyclonal antibody therapeutics developer. The company's proprietary Tc Bovine® platform uses genetically engineered cattle to generate large quantities of human antibodies designed to target specific infectious agents and disease-related antigens. This technology combines the broad-spectrum protection of polyclonal antibody therapies with the scalability and consistency needed for clinical development and commercial deployment. The company's primary focus centers on infectious disease applications.
Institutional investment in the company has shown modest growth. Hedge funds and institutional investors have collectively accumulated positions valued at approximately 7.82 percent of outstanding shares. Recent institutional purchases include investments by ADAR1 Capital Management, Dimensional Fund Advisors, the State of Wyoming, Virtu Financial, and State Street Corp, with individual positions ranging from $30,000 to $49,000 in value.
